Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Corey Deberry-Seguine

Physician Assistant Gilbert, AZ Physician Assistant

NPI 1669921524 CMS profile 10750141

4915 E Baseline Rd Ste 112, Gilbert, AZ 85234

Open in the dashboard

General payments

$6,983

298 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Corey Deberry-Seguine of Gilbert, AZ is reported in the CMS Open Payments database as having received $6,983 across 298 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,215 110
2024 General $1,471 53
2023 General $1,372 69
2022 General $546 34
2021 General $1,380 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Corey Deberry-Seguine
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Corey Deberry-Seguine were reported at $2,215. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Corey Deberry-Seguine Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,380 $132 $37–$438 $132
2022 $546 $155 $48–$522 $149
2023 $1,372 $167 $52–$557 $160
2024 $1,471 $178 $55–$600 $164
2025 $2,215 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Biohaven Pharmaceuticals, Inc. $909 9 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $716 41 payments
  3. Regeneron Healthcare Solutions, Inc. $662 28 payments
  4. AstraZeneca Pharmaceuticals LP $647 13 payments
  5. AbbVie, Inc. $379 23 payments
  6. CSL Behring $360 13 payments
  7. Grifols USA, LLC $347 18 payments
  8. Genzyme Corporation $338 13 payments
  9. GlaxoSmithKline, LLC. $324 20 payments
  10. ADMA BioManufacturing LLC $265 25 payments
  11. Other $2,035 95 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,707 269 payments
  2. Consulting Fee $1,065 26 payments
  3. Education $211 3 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT $979 13 payments
  2. TEZSPIRE $395 4 payments
  3. DUPIXENT Immunology $389 14 payments
  4. CUVITRU $379 20 payments
  5. Xembify $347 18 payments
  6. DUPIXENT Immunology And Inflammation $347 14 payments
  7. DUPIXENT Inflammation And Immunology $315 14 payments
  8. AIRSUPRA $294 4 payments
  9. BREZTRI $289 3 payments
  10. FASENRA $282 3 payments
  11. Other $3,664 186 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

417

Median for Physician Assistant: 241

Drug cost

$157,398

Median for Physician Assistant: $4,110

Branded share of claims

39.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 28 $102,632
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 27 $20,141
Xhance Fluticasone Propionate Brand 14 $8,516
Symbicort Budesonide/Formoterol Fumarate Brand 20 $7,822
Cromolyn Sodium Generic 13 $3,777
Epinephrine Generic 15 $3,188
Qvar Redihaler Beclomethasone Dipropionate Brand 11 $2,986
Azelastine Hcl Generic 63 $2,489
Albuterol Sulfate Hfa Albuterol Sulfate Brand 52 $1,810
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 14 $1,669

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$312 28 —
TEZSPIRE
$189 — —
BREZTRI
$125 — —
XOLAIR
$103 — —
AYVAKIT
$99 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

298 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record